We Are Medicating What We Should Be Training

In modern medicine, progress is often defined by efficiency. Faster results. Less effort. Measurable outcomes in shorter periods of time.

By those standards, we are entering a remarkable era.

Weight loss, once the product of sustained behavioral change, can now be achieved pharmacologically. Appetite can be suppressed. Caloric intake can be reduced without the psychological strain that has historically accompanied dieting. For many patients, the results are undeniable.

But beneath this progress lies a more complex question, one that is not being asked often enough:

What happens when physiology is bypassed instead of trained?

The Illusion of Resolution

The rapid adoption of weight-loss pharmacotherapies, particularly GLP-1 receptor agonists, represents a fundamental shift in how we approach metabolic health.

To be clear, these medications are effective. They produce meaningful reductions in body weight and improvements in certain metabolic markers. From a short-term clinical standpoint, they work.

But weight loss is not synonymous with health.

And when examined through a physiological lens, the picture becomes less straightforward.

A consistent finding across the literature is that a portion of weight lost through pharmacological intervention includes lean mass, skeletal muscle. This is not a trivial detail. Muscle is not simply aesthetic tissue; it is metabolically active, functionally essential, and tightly linked to long-term health outcomes.

Loss of muscle contributes to reductions in resting metabolic rate, impairments in physical function, and increased vulnerability over time. In older populations, this trajectory is not hypothetical, it is predictive.

We are, in many cases, reducing body weight while simultaneously eroding the very tissue that supports long-term metabolic stability.

The Predictable Decline

At the same time, a parallel process is unfolding, one that has been well documented for decades.

Beginning as early as the fourth decade of life, individuals experience a gradual decline in muscle mass (sarcopenia) and strength (dynapenia). This decline is associated with increased risk of falls, loss of independence, chronic disease progression, and mortality.

Importantly, this process is not inevitable in the way it is often perceived.

It is, to a large extent, the consequence of disuse.

The human body adapts to the demands placed upon it. When those demands diminish, particularly in the absence of resistance training, muscle is not maintained. Strength declines. Function deteriorates.

This is not a failure of aging. It is a failure of stimulus.

A Mismatch of Problems and Solutions

What we are witnessing is not simply the rise of new treatments. It is a mismatch between the nature of the problem and the type of solution being applied.

Muscle loss, metabolic decline, and reduced physical capacity are fundamentally physiological and behavioral issues. They develop over time, influenced by activity patterns, mechanical loading, nutrition, and consistency.

Yet increasingly, they are being addressed with pharmacological tools.

This substitution is not neutral.

Medication can reduce weight. It cannot replicate the adaptive processes triggered by resistance training, the mechanical tension, neuromuscular recruitment, and metabolic signaling required to preserve and build muscle tissue.

There is no pharmaceutical equivalent to progressive overload.

The Simplicity We Continue to Avoid

The most effective intervention for preserving muscle and maintaining metabolic health has not changed.

It is structured resistance training.

Performed consistently, two to four times per week, with progressive increases in load or intensity, resistance training stimulates the very adaptations that decline with age. It preserves lean mass. It maintains strength. It supports metabolic function.

Paired with adequate protein intake and sustained over time, it remains the most reliable strategy we have.

This is not new information. It is not controversial. It is simply underutilized.

Perhaps because it requires effort. Perhaps because its benefits accrue slowly. Or perhaps because it does not lend itself to rapid, scalable solutions.

Redefining Progress

None of this is an argument against pharmacology. Medications have a role. For certain individuals, they may be necessary, even life-changing.

But they are not a replacement for physiology.

If anything, their rise should prompt a more careful integration, not a displacement, of foundational principles.

Progress in health should not be defined solely by how quickly outcomes can be achieved, but by how well those outcomes are sustained.

And sustainability, in this context, is built on muscle.

The Path Forward

As medicine, fitness, and public health continue to intersect, the need for clear, evidence-based interpretation becomes more urgent.

We are not choosing between innovation and tradition. We are deciding whether innovation will complement or override what we already understand to be true.

The body does not respond to intention. It responds to stimulus.

And no matter how advanced our interventions become, that principle remains unchanged.

Dr. Fred Peters is an exercise physiologist and a Professor of Applied Exercise Science. His work focuses on resistance training, aging, and long-term metabolic health.

Selected Publications

• Peters, F. (2026). Sarcopenia and Dynapenia: Harnessing Resistance Training to Counter Age-Related Muscle Decline. ACSM’s Health & Fitness Journal.

[Read Article →]

• Peters, F. (2025). The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic. Sports Medicine and Therapy.

[Read Article →]